BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.8% in the second quarter, Holdings Channel reports. The institutional investor owned 95,371 shares of the biotechnology company’s stock after selling 2,718 shares during the quarter. Mutual of America Capital Management LLC’s holdings in BioMarin Pharmaceutical were worth $5,243,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Goldman Sachs Group Inc. grew its position in shares of BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Covea Finance grew its position in shares of BioMarin Pharmaceutical by 27.3% during the second quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock worth $7,437,000 after buying an additional 29,000 shares in the last quarter. GAMMA Investing LLC grew its position in shares of BioMarin Pharmaceutical by 154.0% during the first quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company’s stock worth $221,000 after buying an additional 1,897 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of BioMarin Pharmaceutical by 12.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 97,261 shares of the biotechnology company’s stock worth $6,875,000 after buying an additional 10,687 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of BioMarin Pharmaceutical by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,064,924 shares of the biotechnology company’s stock worth $75,279,000 after buying an additional 9,837 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BMRN shares. Zacks Research downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wolfe Research set a $95.00 price target on shares of BioMarin Pharmaceutical and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. UBS Group lifted their price objective on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $93.26.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $53.81 on Wednesday. The company has a market cap of $10.33 billion, a PE ratio of 15.97, a P/E/G ratio of 0.67 and a beta of 0.33. The company has a fifty day moving average price of $55.52 and a two-hundred day moving average price of $57.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. BioMarin Pharmaceutical Inc. has a 12 month low of $51.56 and a 12 month high of $73.51.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.